Pan Wenjue, Teng Qibei, Chen Huiqiao, Hu Liangning, Yue Xiaoyan, Qian Zijun, Dong Ruoyu, Zhou Hongyu, Zhao Xiujie, Xiao Haowen, Wang Shufen
Department of Hematology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, No. 3 Qingchun East Rd., Hangzhou, 310016, Zhejiang province, PR China.
Heliyon. 2024 Sep 4;10(18):e37436. doi: 10.1016/j.heliyon.2024.e37436. eCollection 2024 Sep 30.
Iron overload, as indicated by evaluated serum ferritin (SF) level, occurs commonly in patients with hematological diseases. To evaluate the association between pre-transplant SF level and outcomes of hematopoietic stem cell transplantation (HSCT), we performed this systematic review and meta-analysis.
PubMed, Embase, Web of Science and the Cochrane Library electronic database were searched from inception to August 2023, and 56 studies with 14149 patients were found to be eligible.
An elevated pre-transplantation SF level was associated with inferior overall survival (hazard ratio [HR],1.77; 95 % confidence interval [CI],1.61-1.96) and disease-free survival (HR, 1.86; 95 % CI, 1.58-2.19), and increased risk of non-relapse mortality (HR, 1.73; 95 % CI, 1.49-2.02), and relapse (HR, 1.46; 95 % CI, 1.29-1.65). However, no meaningful association was observed between SF levels and acute graft-versus-host disease (GVHD) (risk ratio [RR], 1.09; 95 % CI, 0.96-1.24), or chronic GVHD (RR, 0.95; 95 % CI, 0.79-1.16). Furthermore, an elevated pre-transplantation SF level was associated with a higher risk of fungal infection (RR, 1.56; 95 % CI, 1.16-2.10), but not with bacterial infection (RR, 1.09; 95 % CI, 0.80-1.50). Moreover, an elevated pre-transplantation SF level was related to a higher risk of death due to relapse/disease progression (RR, 1.72; 95 % CI, 1.33-2.23) and infection (RR, 2.21; 95 % CI, 1.55-3.15), but not death due to GVHD (RR, 1.18; 95 % CI, 0.79-1.77).
A higher pre-transplantation SF level was significantly associated with a higher risk of relapse/disease progression and infections, which contributed to worse survival in patients undergoing HSCT. In particular, a higher SF level was related to a higher risk of fungal infection, indicating that patients with a higher pre-transplantation SF level require more attention regarding the risk of fungal infection after HSCT.
血清铁蛋白(SF)水平升高所提示的铁过载在血液病患者中普遍存在。为评估移植前SF水平与造血干细胞移植(HSCT)结局之间的关联,我们进行了此项系统评价和荟萃分析。
检索了从建库至2023年8月的PubMed、Embase、Web of Science和Cochrane图书馆电子数据库,共纳入56项研究,涉及14149例患者。
移植前SF水平升高与总生存期较差(风险比[HR],1.77;95%置信区间[CI],1.61 - 1.96)、无病生存期较差(HR,1.86;95% CI,1.58 - 2.19)、非复发死亡率增加(HR,1.73;95% CI,1.49 - 2.02)及复发风险增加(HR,1.46;95% CI,1.29 - 1.65)相关。然而,未观察到SF水平与急性移植物抗宿主病(GVHD)(风险比[RR],1.09;95% CI,0.96 - 1.24)或慢性GVHD(RR,0.95;95% CI,0.79 - 1.16)之间存在有意义的关联。此外,移植前SF水平升高与真菌感染风险较高(RR,1.56;95% CI,1.16 - 2.10)相关,但与细菌感染无关(RR,1.09;95% CI,0.80 - 1.50)。而且,移植前SF水平升高与因复发/疾病进展导致的死亡风险较高(RR,1.72;95% CI,1.33 - 2.23)及感染导致的死亡风险较高(RR,2.21;95% CI,1.55 - 3.15)相关,但与GVHD导致的死亡无关(RR,1.18;95% CI,0.79 - 1.77)。
移植前较高的SF水平与复发/疾病进展及感染风险显著相关,这导致接受HSCT的患者生存情况较差。特别是,较高的SF水平与真菌感染风险较高相关,这表明移植前SF水平较高的患者在HSCT后需要更多关注真菌感染风险。